6月17日，Abivax S.A.盘中上涨5.15%，报102.48美元/股，成交额5767.44万美元。
消息面上，公司核心药物obefazimod三期ABTECT维持试验此前因50mg组出现多例癌症病例，股价自130美元附近暴跌至约70美元，跌幅一度近50%。此后部分投资者认为癌症病例更可能与患者年龄相关，前期市场反应或过度。尽管Wedbush Securities此前指出该药面临黑框警告风险上升，且The Schall Law Firm已对公司启动证券欺诈调查，但当前股价自低位持续回升，连续两个交易日录得超5%涨幅，反映多空博弈中买方力量阶段性占优。
Abivax Sa是一家临床阶段的生物技术公司，专注于开发利用人体自然调节机制来稳定慢性炎症性疾病免疫反应的疗法，其主要候选药物obefazimod正处于治疗溃疡性结肠炎的3期开发阶段。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.